Teva's CGRP Inhibitor Fails In Chronic Cluster Headaches, Continues In Episodic

Unlike the migraine space, there is only one competitor for Teva's CGRP inhibitor in cluster headaches, but that opportunity narrowed with fremanezumab's failure in chronic cluster headaches, though a trial in episodic cluster headaches is ongoing.

Closed up finger on keyboard with word CLINICAL TRIALS

Teva Pharmaceutical Industries Ltd.'s latest update on fremanezumab in cluster headaches will lessen the calcitonin gene-related peptide (CGRP) inhibitor's potential market by a few hundred thousand patients, but the biologic's main opportunity lies in the much larger migraine headache market.

Teva said on June 15 that it will discontinue a Phase III clinical trial testing fremanezumab in the prevention of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category